Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AQXP

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

Aquinox Pharmaceuticals logo

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

Key Stats

Today's Range
$15.28
$17.45
50-Day Range
$3.68
$4.03
52-Week Range
$2.00
$3.84
Volume
802,176 shs
Average Volume
239,362 shs
Market Capitalization
$360.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive AQXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQXP Stock News Headlines

Mirum Pharmaceuticals, Inc. (MIRM)
Why Aquinox Pharma (AQXP) Stock Might be a Great Pick
917 Trades… Zero Losses?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
See More Headlines

AQXP Stock Analysis - Frequently Asked Questions

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) posted its earnings results on Thursday, November, 8th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2018
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AQXP
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-31,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$25 million
Book Value
$3.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$360.87 million
Optionable
Not Optionable
Beta
-7.37
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:AQXP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners